Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model.
We hypothesize that infusion of chemotherapeutic agents directly into the fourth ventricle potentially may play a role in treating malignant posterior fossa brain tumors. Accordingly, we used a piglet model developed in our laboratory to test the safety of etoposide infusions into the fourth ventricle and to study the pharmacokinetics associated with these infusions. In 5 piglets, closed-tip silicone catheters were inserted into the fourth ventricle and lumbar cistern. Five consecutive daily infusions of etoposide (0.5 mg) were administered via the fourth ventricle catheter. Serum and CSF from both catheters were sampled for measurement of etoposide level by reversed-phase high performance liquid chromatography (HPLC). For CSF samples, area under the concentration-time curve (AUC) was calculated. Piglets underwent daily neurological examinations, a 4.7 Tesla MRI scan, and then were sacrificed for post-mortem brain examination. No neurological deficits or signs of meningitis were caused by intraventricular chemotherapy infusions. MRI scans showed catheter placement within the fourth ventricle but no signal changes in the brain stem or cerebellum. In all piglets, the mean fourth ventricular CSF peak etoposide level exceeded the mean peak lumbar etoposide levels by greater than 10-fold. Statistically significant differences between fourth ventricle and lumbar AUC were noted at peaks (DeltaAUC = 3384196 ng h/ml with 95%CI: 1758625, 5009767, P = 0.0044) and at all collection time points (DeltaAUC = 1422977 ng h/ml with 95%CI: 732188, 2113766, P = 0.0046) but not at troughs (DeltaAUC = -29546 ng h/ml (95%CI: -147526, 88434.2, P = 0.5251). Serum etoposide was absent at two and four hours after intraventricular infusions in all animals. Pathological analysis demonstrated meningitis, choroid plexitis, and ependymitis in the fourth and occasionally lateral ventricles. Etoposide can be infused directly into the fourth ventricle without clinical or radiographic evidence of damage. Autopsy examination revealed ventriculitis and meningitis which did not have a clinical correlate. Etoposide does not distribute evenly throughout CSF spaces after administration into the fourth ventricle, and higher peak CSF levels are observed in the fourth ventricle than in the lumbar cistern.
Sandberg
David I
DI
Department of Neurological Surgery, University of Miami Miller School of Medicine and Miami Children's Hospital, Ambulatory Care Building Suite 3109, Miami, FL 33155, USA. dsandberg@med.miami.edu
Crandall
Kenneth M
KM
Koru-Sengul
Tulay
T
Padgett
Kyle R
KR
Landrum
John
J
Babino
Darwin
D
Petito
Carol K
CK
Solano
Juan
J
Gonzalez-Brito
Manuel
M
Kuluz
John W
JW
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics* / Q000494:pharmacology; D019540:Area Under Curve; D002452:Cell Count; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D016001:Confidence Intervals; D004195:Disease Models, Animal; D005047:Etoposide / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics* / Q000494:pharmacology; D020546:Fourth Ventricle / Q000187:drug effects*; D015192:Infratentorial Neoplasms / Q000188:drug therapy / Q000473:pathology*; D008279:Magnetic Resonance Imaging / Q000379:methods; D009460:Neurologic Examination / Q000379:methods; D013552:Swine; D013997:Time Factors
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide
Drugs. 1990 Mar;39(3):438-90
2184009
Cancer Chemother Pharmacol. 2001 Aug;48(2):134-40
11561779
Childs Nerv Syst. 1999 Oct;15(10):554-62
10550586
Neurology. 1985 Sep;35(9):1274-8
3839573
Int J Clin Pharmacol Ther. 2003 Dec;41(12):606-7
14692713
Neurosurgery. 2000 Jul;47(1):49-54; discussion 54-5
10917346
Br J Cancer. 2001 Jun 1;84(11):1453-9
11384092
J Neurosurg Pediatr. 2008 May;1(5):373-80
18447671
Clin Neurosurg. 1997;44:571-85
10080028
Clin Oncol. 1981 Jun;7(2):123-9
7249435
Int J Radiat Oncol Biol Phys. 1986 Apr;12(4):453-8
3516948
Neurol Clin. 1991 Nov;9(4):955-67
1758434
Neurochirurgie. 1982;28 Suppl 1:1-229
7110502
Cancer. 1978 Jun;41(6):2431-7
274993
Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):1869-76
6818190
J Neurosurg. 1997 Nov;87(5):694-9
9347977
Cancer. 1975 Feb;35(2):291-305
1053934
J Neurooncol. 1998 Jun-Jul;38(2-3):213-8
9696374
Curr Opin Neurol. 1999 Dec;12(6):681-5
10676748
N Engl J Med. 2005 Mar 10;352(10):978-86
15758008
J Neurooncol. 2003 Sep;64(3):239-47
14558599
Cancer Treat Rep. 1977 Jul;61(4):733-43
577896